NYSE · Biotechnology

Evommune, Inc. (EVMN) Stock

$6.25 -2.50% NYSE: EVMN Healthcare

Valuation

MetricValue
Price$6.25
Market Cap$226.83M
P/E Ratio-2.45
P/B Ratio0.90
P/S Ratio25.11
EPS (TTM)$-2.18
52-Week High$33.20
52-Week Low$6.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-62.63%
ROA-31.35%
ROCE-35.82%
Gross Margin-623.08%
Operating Margin-623.08%
Net Margin-946.68%
Debt/Equity0.03
Current Ratio8.50

Annual Financials (USD)

Metric202320242025
Revenue$5.0M$7.0M$13.0M
Operating Profit$-38.0M$-70.0M$-81.0M
Net Profit$-34.0M$-67.0M$-69.0M
EPS$-1.13$-2.27$-2.18
Op Margin-757.0%-1000.2%-623.6%

Balance Sheet (USD)

Metric202320242025
Total Assets$82.0M$76.0M$225.0M
Total Liabilities$160.0M$220.0M$19.0M
Cash$29.0M$16.0M$44.0M
Borrowings$151.0M$193.0M$2.0M

Latest News

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal Zacks · Jun 30, 2026 Top Midday Decliners MT Newswires · Jun 29, 2026 Evommune terminates oral drug’s development in CSU Clinical Trials Arena · Jun 29, 2026 Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN) InvestorsHub · Jun 29, 2026 Evommune's Trial of EVO756 Misses Primary Endpoint; Shares Tumble Pre-Bell MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric202320242025
Operating Cash Flow$-30.0M$-58.0M$-76.0M
Investing Cash Flow$-49.0M$-4.0M$-116.0M
Financing Cash Flow$0$0$-1.0M
Net Cash Flow$29.0M$-13.0M$28.0M
Free Cash Flow$-30.0M$-58.0M$-77.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.05
EV / EBITDA-2.08
FCF Yield-29.73%
Quick Ratio11.68
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held3.18%
Institutions Held116.21%
Institutions Float Held120.02%
Institutional HolderSharesReport Date
Eqt Fund Management S.a R.l.4,929,6332026-03-31
RA Capital Management, L.P.3,494,6382026-03-31
Pivotal bioVenture Partners Investment Advisor, LLC1,926,9432026-03-31
Andera Partners1,897,3622026-03-31
RTW Investments LP1,502,2352026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARTVArtiva Biotherapeutics, Inc. $6.94 +2.06% -2.06 $339.30M 0.00%
CDXSCodexis, Inc. $1.41 +3.68% -4.05 $151.66M 0.00%
CLYMClimb Bio, Inc. $11.00 +1.29% -13.18 $629.89M 0.00%
EYPTEyePoint, Inc. $3.40 -1.73% -0.91 $285.06M 0.00%
FTREFortrea Holdings Inc. $20.84 +2.31% -21.51 $1.98B 0.00%

About Evommune, Inc.

Evommune, Inc. is led by CEO Luis C. Pena, employs 45 people, headquartered in US, publicly traded since 2025.

Evommune, Inc. (EVMN) stock trades at $6.25 with a market capitalization of $226.83M. The stock is valued at a price-to-earnings (P/E) ratio of -2.45, price-to-book of 0.90, price-to-sales of 25.11. Over the past 52 weeks the stock has ranged between $6.04 and $33.20, and currently trades 81.2% below its 52-week high.

On profitability, Evommune, Inc. generates a return on equity (ROE) of -62.63%, return on capital employed of -35.82%, an operating margin of -623.08%, a net profit margin of -946.68%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides